TY - JOUR
T1 - Consensus Middle East and North Africa Registry on Inborn Errors of Immunity
AU - MENA-I. E. I. Study Group
AU - Aghamohammadi, Asghar
AU - Rezaei, Nima
AU - Yazdani, Reza
AU - Delavari, Samaneh
AU - Kutukculer, Necil
AU - Topyildiz, Ezgi
AU - Ozen, Ahmet
AU - Baris, Safa
AU - Karakoc-Aydiner, Elif
AU - Kilic, Sara Sebnem
AU - Kose, Hulya
AU - Gulez, Nesrin
AU - Genel, Ferah
AU - Reisli, Ismail
AU - Djenouhat, Kamel
AU - Tahiat, Azzeddine
AU - Boukari, Rachida
AU - Ladj, Samir
AU - Belbouab, Reda
AU - Ferhani, Yacine
AU - Belaid, Brahim
AU - Djidjik, Reda
AU - Kechout, Nadia
AU - Attal, Nabila
AU - Saidani, Khalissa
AU - Barbouche, Ridha
AU - Bousfiha, Aziz
AU - Sobh, Ali
AU - Rizk, Ragheed
AU - Elnagdy, Marwa H.
AU - Al-Ahmed, Mona
AU - Al-Tamemi, Salem
AU - Nasrullayeva, Gulnara
AU - Adeli, Mehdi
AU - Al-Nesf, Maryam
AU - Hassen, Amel
AU - Mehawej, Cybel
AU - Irani, Carla
AU - Megarbane, Andre
AU - Quinn, Jessica
AU - Chavoshzadeh, Zahra
AU - Mahdaviani, Seyed Alireza
AU - Nabavi, Mohammamd
AU - Tavakol, Marzieh
AU - Behniafard, Nasrin
AU - Momen, Tooba
AU - Azizi, Gholamreza
AU - Bemanian, Mohammad Hassan
AU - Arshi, Saba
AU - Molatefi, Rasol
N1 - Funding Information:
We would like to thank all the patients and the healthcare services involved in this project. Qatar National PID Registry work was supported by a grant fund from Hamad Medical Corporation (MRC#16299/66).
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/8
Y1 - 2021/8
N2 - Background: Inborn errors of immunity (IEIs) are a heterogeneous group of genetic defects of immunity, which cause high rates of morbidity and mortality mainly among children due to infectious and non-infectious complications. The IEI burden has been critically underestimated in countries from middle- and low-income regions and the majority of patients with IEI in these regions lack a molecular diagnosis. Methods: We analyzed the clinical, immunologic, and genetic data of IEI patients from 22 countries in the Middle East and North Africa (MENA) region. The data was collected from national registries and diverse databases such as the Asian Pacific Society for Immunodeficiencies (APSID) registry, African Society for Immunodeficiencies (ASID) registry, Jeffrey Modell Foundation (JMF) registry, J Project centers, and International Consortium on Immune Deficiency (ICID) centers. Results: We identified 17,120 patients with IEI, among which females represented 39.4%. Parental consanguinity was present in 60.5% of cases and 27.3% of the patients were from families with a confirmed previous family history of IEI. The median age of patients at the onset of disease was 36 months and the median delay in diagnosis was 41 months. The rate of registered IEI patients ranges between 0.02 and 7.58 per 100,000 population, and the lowest rates were in countries with the highest rates of disability-adjusted life years (DALY) and death rates for children. Predominantly antibody deficiencies were the most frequent IEI entities diagnosed in 41.2% of the cohort. Among 5871 patients genetically evaluated, the diagnostic yield was 83% with the majority (65.2%) having autosomal recessive defects. The mortality rate was the highest in patients with non-syndromic combined immunodeficiency (51.7%, median age: 3.5 years) and particularly in patients with mutations in specific genes associated with this phenotype (RFXANK, RAG1, and IL2RG). Conclusions: This comprehensive registry highlights the importance of a detailed investigation of IEI patients in the MENA region. The high yield of genetic diagnosis of IEI in this region has important implications for prevention, prognosis, treatment, and resource allocation.
AB - Background: Inborn errors of immunity (IEIs) are a heterogeneous group of genetic defects of immunity, which cause high rates of morbidity and mortality mainly among children due to infectious and non-infectious complications. The IEI burden has been critically underestimated in countries from middle- and low-income regions and the majority of patients with IEI in these regions lack a molecular diagnosis. Methods: We analyzed the clinical, immunologic, and genetic data of IEI patients from 22 countries in the Middle East and North Africa (MENA) region. The data was collected from national registries and diverse databases such as the Asian Pacific Society for Immunodeficiencies (APSID) registry, African Society for Immunodeficiencies (ASID) registry, Jeffrey Modell Foundation (JMF) registry, J Project centers, and International Consortium on Immune Deficiency (ICID) centers. Results: We identified 17,120 patients with IEI, among which females represented 39.4%. Parental consanguinity was present in 60.5% of cases and 27.3% of the patients were from families with a confirmed previous family history of IEI. The median age of patients at the onset of disease was 36 months and the median delay in diagnosis was 41 months. The rate of registered IEI patients ranges between 0.02 and 7.58 per 100,000 population, and the lowest rates were in countries with the highest rates of disability-adjusted life years (DALY) and death rates for children. Predominantly antibody deficiencies were the most frequent IEI entities diagnosed in 41.2% of the cohort. Among 5871 patients genetically evaluated, the diagnostic yield was 83% with the majority (65.2%) having autosomal recessive defects. The mortality rate was the highest in patients with non-syndromic combined immunodeficiency (51.7%, median age: 3.5 years) and particularly in patients with mutations in specific genes associated with this phenotype (RFXANK, RAG1, and IL2RG). Conclusions: This comprehensive registry highlights the importance of a detailed investigation of IEI patients in the MENA region. The high yield of genetic diagnosis of IEI in this region has important implications for prevention, prognosis, treatment, and resource allocation.
KW - Burden of disease
KW - Epidemiology
KW - Inborn errors of immunity
KW - Molecular diagnosis
KW - Primary immunodeficiency
UR - http://www.scopus.com/inward/record.url?scp=85112155942&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85112155942&partnerID=8YFLogxK
U2 - 10.1007/s10875-021-01053-z
DO - 10.1007/s10875-021-01053-z
M3 - Article
C2 - 34052995
AN - SCOPUS:85112155942
SN - 0271-9142
VL - 41
SP - 1339
EP - 1351
JO - Journal of Clinical Immunology
JF - Journal of Clinical Immunology
IS - 6
ER -